BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:frevecitinib readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of frevecitinib\, from ClinicalTrials.gov es
 timates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07532265-1543@assetmemo.bio
DTSTAMP:20261121T004422Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:frevecitinib: Phase 2 readout est. (NCT07532265)
DESCRIPTION:frevecitinib\, phase 2\, Asthma.\nStudy: A Clinical Study to Ev
 aluate the Efficacy and Safety of Frevecitinib (KN-002) in Patients With S
 evere Asthma\nEstimated primary completion: 30 November 2027. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/frevecitinib#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT07532265
URL:https://assetmemo.bio/drug/frevecitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
